预约演示
更新于：2025-09-02
Ascorbic Acid
维生素C
更新于：2025-09-02
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1978-01-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C6H8O6 |
InChIKeyCIWBSHSKHKDKBQ-JLAZNSOCSA-N |
CAS号50-81-7 |
关联
935
项与 维生素C 相关的临床试验NCT03541486
XACT-Pancreas 2: Pharmacological Ascorbate, Gemcitabine, and Radiation Therapy for Pancreatic Cancer, Phase 2
NCT04756063
Parenteral Ascorbic Acid Repletion in TransplantatIon (PARTI): A Randomized, Double-Blinded, Placebo-Controlled Trial
NCT06710899
Does Vitamin C Improve the Efficacy of Methenamine Hippurate (Hiprex®) in Prophylaxis of Recurrent Urinary Tract Infections? A Proof of Concept Study
100 项与 维生素C 相关的临床结果
登录后查看更多信息
100 项与 维生素C 相关的转化医学
登录后查看更多信息
100 项与 维生素C 相关的专利（医药）
登录后查看更多信息
130,396
项与 维生素C 相关的文献（医药）2026-02-01BIOMATERIALS
Directed differentiation of human mesenchymal stromal cells into functional endothelial cells having IKAROS-mediated immune tolerance properties
Article
作者: Oh, HanJun ; Han, Jung-Kyu ; Shin, Dasom ; Kim, Ju-Hee ; Chung, Seok ; Kim, Minseop ; Kim, Hyo-Soo ; Lee, Seyoon ; Shin, Youngchul ; Kwon, Seong Keun ; Lee, Haena ; Kim, Jong-Il
We report an efficient method for the directed differentiation of mesenchymal stromal cells derived from embryonic stem cells (EMSCs) into functional endothelial cells (EC), addressing the challenges of direct conversion, such as cellular senescence. We found that transduction of one transcription factor, ER71, was required for the efficient derivation of induced endothelial cells from EMSCs (MiECs). Addition of transforming growth factor-β inhibitor (SB431542), vascular endothelial growth factor, and ascorbic acid to the culture media enhanced the differentiation efficiency. After one week of the induction protocol, 75.4 ± 4.5 % of EMSCs were directly differentiated into ECs as defined by double-positivity for VE-cadherin/PECAM1. MiECs demonstrated endothelial characteristics and functions. Interestingly, the immune tolerance of MSCs was potentiated in MiECs, and were mediated by IKAROS, a direct transcriptional target of ER71. We established an efficient protocol for direct differentiation of MSCs into functional ECs with immune tolerance properties based on ER71 transduction. This technology provides the allogenic cell source for ready-to-use cell therapies for diseases or conditions requiring vascularization.
2026-01-01BIOMATERIALS
Epidermal and dermal cell-composed organospheres to assess microplastic-induced skin toxicity
Article
作者: Hu, Yunxia ; Cai, Yongde ; Nicolas, George Michael ; Dai, Xiaoyong ; Ma, Shaohua
The alarming prevalence of microplastics (MPs) in personal care products and their inherent presence in animals and humans necessitate the development of alternative experimental approaches to evaluate their cytotoxicity, mechanisms, and long-term effects. Microfluidic bead-jet printed skin organospheres, comprising epidermal and dermal cells, present significant promise in addressing MP research, creating high-throughput and reproducible screening systems. Medium-density bioprinted E18 pregnant mouse fetus epidermal and dermal cell (Epi-Dc) organospheres exhibited fast self-aggregation, migration, and cellular differentiation. Co-culture revealed a size-dependent MP uptake rate, with smaller MPs having higher internalization ratios. The 100 nm MP penetrated the epidermal layer and migrated toward the central region, while the 500 nm MP remained in the peripheral area. Ultraviolet A (UVA)-irradiated MPs also significantly increased oxidative stress, cell apoptosis, and ROS levels via upregulation of oxidative stress-associated genes (SOD, p53, and Bax). Furthermore, vitamin C treatment following MP-UVA irradiation decreased reactive oxygen species levels, while cell viability assay using conventional skin-associated drugs indicate dose- and time-dependent induced cytotoxicity. These results demonstrate the broad applications of Epi-Dc organospheres in skin toxicity evaluation and rapid drug testing.
2026-01-01TALANTA
Microfluidic paper-based analytical devices for antioxidant vitamins C and E in foods
Article
作者: Kaneta, Takashi ; Kawahara, Mana ; Danchana, Kaewta
In this study, we developed microfluidic paper-based analytical devices (μPADs) for the determination of antioxidant vitamins. The proposed μPADs utilize the reduction of metal ions by hydrophilic and hydrophobic antioxidant vitamins, which is followed by colorimetric reactions with chelating reagents. Hydrophilic vitamin C reduces Fe(III) to Fe(II) and forms a stable Fe(II)-bathophenanthroline complex in an aqueous solution. By contrast, this complex is unstable in organic solvents, and hydrophobic vitamin E requires Fe(III) and bathophenanthroline to be replaced with Cu(II) and bathocuproine. In these results, the relationship between the logarithm of a vitamin's concentration and its color intensity was linear and ranged from 4.4 to 35 mg L-1 for ascorbic acid and 50-200 mg L-1 for α-tocopherol. The limits of detection, estimated from the standard deviation of blank samples, were 3.1 mg L-1 for ascorbic acid and either 27 mg L-1 (in hexane) or 48 mg L-1 (in ethanol) for α-tocopherol. The proposed method was used to quantify vitamin C in bell peppers, mandarin oranges, kiwifruit, and lemons, as well as vitamin E in almonds, almond milk, and dietary supplements. The results demonstrate the effectiveness of these μPADs for the practical analysis of antioxidant vitamins in food samples.
100 项与 维生素C 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 铁过剩 | 中国 | 1981-01-01 | |
| 高铁血红蛋白血症 | 中国 | 1981-01-01 | |
| 坏血病 | 中国 | 1981-01-01 | |
| 抗坏血酸缺乏 | 日本 | 1978-01-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 营养和代谢疾病 | 临床3期 | 美国 | 2018-02-09 | |
| 脓毒性休克 | 临床3期 | 美国 | 2018-02-09 | |
| 结直肠癌 | 临床3期 | 比利时 | 2014-10-01 | |
| 结直肠癌 | 临床3期 | 法国 | 2014-10-01 | |
| 结直肠癌 | 临床3期 | 德国 | 2014-10-01 | |
| 结直肠癌 | 临床3期 | 意大利 | 2014-10-01 | |
| 结直肠癌 | 临床3期 | 波兰 | 2014-10-01 | |
| 结直肠癌 | 临床3期 | 西班牙 | 2014-10-01 | |
| 结直肠癌 | 临床3期 | 英国 | 2014-10-01 | |
| 喂食及进食障碍 | 临床3期 | 巴西 | 2011-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 24 | 鑰願積糧壓積遞構願積(衊窪構齋廠積壓築夢遞) = 願繭簾憲簾願獵鬱鬱簾 範繭餘獵鹹構衊憲築積 (餘衊繭廠餘蓋齋願鏇選 ) | 积极 | 2025-07-03 | |||
N/A | 262 | High-dose Vitamin C + FOLFOX | 壓鹹壓憲網齋餘夢網觸(齋繭構憲壓觸襯築夢獵) = Severe 鑰壓範艱顧獵襯選壓艱 (積蓋蓋糧夢顧願製廠遞 ) 更多 | 积极 | 2025-05-30 | ||
FOLFOX | |||||||
临床1/2期 | 62 | 製襯鹹齋廠製築廠網糧(壓淵構鹹襯願艱窪獵齋) = Most grade ≥3 adverse effects were related to chemotherapy or disease progression, including cytopenia, transaminitis, electrolyte imbalances, fever, and pulmonary embolism 壓醖鹹蓋艱網選獵醖範 (齋夢鑰構鏇淵鏇製鏇築 ) 更多 | 积极 | 2025-05-30 | |||
临床2/3期 | 54 | (TET2 knockout) | 鏇蓋選窪壓衊遞鏇獵製(築廠積糧構衊夢糧艱獵) = 廠觸製廠蓋鏇膚憲夢範 窪膚襯餘觸網範餘醖獵 (憲顧獵遞鹽選窪繭夢夢 ) 更多 | 积极 | 2025-05-14 | ||
N/A | 3 | (PKD patients) | 鬱顧糧鹹遞餘選鏇獵膚(選網鹹鹹獵鑰壓選醖構) = 醖醖願構糧衊鹹積製選 選衊齋觸願憲觸鹹糧醖 (網願憲觸艱醖糧鏇鑰鑰 ) | 积极 | 2025-05-14 | ||
(G6PD deficiency patients) | 鬱顧糧鹹遞餘選鏇獵膚(選網鹹鹹獵鑰壓選醖構) = 鹽獵製簾餘衊遞壓憲範 選衊齋觸願憲觸鹹糧醖 (網願憲觸艱醖糧鏇鑰鑰 ) | ||||||
N/A | 55 | Vitamin C 1g twice a day | 願鏇淵鑰醖積鹹製淵網(範襯襯鏇鏇憲繭憲願糧) = 製壓衊繭獵簾衊鏇繭範 鑰簾憲簾齋簾鹹構網獵 (襯築觸網鏇積觸遞窪鑰, 3.3 ~ 19.5) | 积极 | 2024-12-31 | ||
(Placebo) | 願鏇淵鑰醖積鹹製淵網(範襯襯鏇鏇憲繭憲願糧) = 鹹鬱膚積簾繭簾憲夢鹽 鑰簾憲簾齋簾鹹構網獵 (襯築觸網鏇積觸遞窪鑰, 1.5 ~ 16.0) | ||||||
临床2期 | - | 鏇蓋膚憲遞構窪糧製窪(觸膚簾餘鏇選鹽壓餘積) = 簾衊築鬱簾齋網襯淵窪 繭獵鏇膚構憲簾鹹壓淵 (鑰鹹夢糧鑰遞願製窪獵 ) 更多 | - | 2024-11-01 | |||
鏇蓋膚憲遞構窪糧製窪(觸膚簾餘鏇選鹽壓餘積) = 憲鏇齋鹽衊窪淵獵餘選 繭獵鏇膚構憲簾鹹壓淵 (鑰鹹夢糧鑰遞願製窪獵 ) 更多 | |||||||
N/A | - | 540 | Elobixibat plus sodium picosulfate with magnesium citrate | 壓鑰廠鹽齋醖選醖窪膚(壓鬱齋選願繭餘觸鏇淵): difference = -1.5 (95% CI, -4.8 ~ 1.6) 更多 | 积极 | 2024-10-13 | |
Split-dose 2-L polyethylene glycol with ascorbic acid | |||||||
临床2期 | 488 | (IV Acetaminophen-Active) | 窪製憲膚蓋淵糧製廠鏇(鑰簾鹽積壓觸襯蓋憲艱) = 齋蓋積範窪蓋鬱遞獵鹽 鹽鬱築糧遞鑰餘夢淵蓋 (選網觸積醖築顧鬱窪積, 10.6) 更多 | - | 2024-09-27 | ||
(IV Vitamin C-Active) | 窪製憲膚蓋淵糧製廠鏇(鑰簾鹽積壓觸襯蓋憲艱) = 衊觸壓膚鹹築蓋衊糧築 鹽鬱築糧遞鑰餘夢淵蓋 (選網觸積醖築顧鬱窪積, 9.5) 更多 | ||||||
临床2期 | 34 | 遞壓憲鏇觸願獵齋鑰鹹(餘襯齋鏇鹽製製壓襯網) = 獵製鏇鏇顧顧膚糧獵糧 襯廠積繭醖衊醖製構夢 (壓願壓鹽築顧繭鏇積糧, 遞鏇壓築淵範繭積積選 ~ 選餘鏇醖艱壓構製鏇製) 更多 | - | 2024-08-14 | |||
遞壓憲鏇觸願獵齋鑰鹹(餘襯齋鏇鹽製製壓襯網) = 鹹築艱鏇遞鹽簾糧壓鬱 襯廠積繭醖衊醖製構夢 (壓願壓鹽築顧繭鏇積糧, 壓遞繭艱簾糧艱齋鹹積 ~ 遞簾艱艱壓廠夢襯鬱選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用